Design and practical evaluation of a shielded application system for  intravenously administered radionuclide therapies.

CONCLUSION:  The presented application system for intravenous radionuclide therapies is feasible, safe, and cost-efficient. It has been shown that Lu-177-PRRT and -RLT can be performed without complications while ensuring nearly complete infusion of the prescribed radiopharmaceutical dose. Radiation exposure of the applying physician and other staff is low. The construction of the shielding box ensures complete shielding of all radionuclides currently used for radiomolecular therapies.
PMID: 32193882 [PubMed - as supplied by publisher]

Source: Nuklearmedizin - March 18, 2020 Category: Radiology Authors: Kühnel C, Winkens T, Niksch T, Greiser J, Schrott S, Drescher R, Freesmeyer M Tags: Nuklearmedizin Source Type: research